John Vincent Thompson, DO | |
2401 W Belvedere Ave, Baltimore, MD 21215 | |
(410) 601-8500 | |
Not Available |
Full Name | John Vincent Thompson |
---|---|
Gender | Male |
Speciality | Orthopedic Surgery |
Experience | 11 Years |
Location | 2401 W Belvedere Ave, Baltimore, Maryland |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407297724 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207XS0114X | Orthopaedic Surgery - Adult Reconstructive Orthopaedic Surgery | H0084829 (Maryland) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Preferred Care Home Health Services | Fort myers, FL | Home health agency |
Cape Coral Hospital | Cape coral, FL | Hospital |
Lee Memorial Hospital | Fort myers, FL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Deiorio Beaulieu And Fuller | 3870516362 | 5 |
News Archive
Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with "biologic" drugs.
In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model.
Since the passage of the Family Smoking Prevention and Tobacco Control Act in 2009, the U.S. Food and Drug Administration has met the ambitious implementation deadlines set forth in the law, the agency said Wednesday at a congressional briefing hosted by the American Association for Cancer Research.
› Verified 6 days ago
Entity Name | Abbott Kagan Ii Md Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1235230087 PECOS PAC ID: 9537052949 Enrollment ID: O20040207000116 |
News Archive
Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with "biologic" drugs.
In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model.
Since the passage of the Family Smoking Prevention and Tobacco Control Act in 2009, the U.S. Food and Drug Administration has met the ambitious implementation deadlines set forth in the law, the agency said Wednesday at a congressional briefing hosted by the American Association for Cancer Research.
› Verified 6 days ago
Entity Name | Deiorio Beaulieu & Fuller |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1639184492 PECOS PAC ID: 3870516362 Enrollment ID: O20060111000249 |
News Archive
Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with "biologic" drugs.
In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model.
Since the passage of the Family Smoking Prevention and Tobacco Control Act in 2009, the U.S. Food and Drug Administration has met the ambitious implementation deadlines set forth in the law, the agency said Wednesday at a congressional briefing hosted by the American Association for Cancer Research.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
John Vincent Thompson, DO 2401 W Belvedere Ave, Baltimore, MD 21215-5216 Ph: (410) 601-8500 | John Vincent Thompson, DO 2401 W Belvedere Ave, Baltimore, MD 21215 Ph: (410) 601-8500 |
News Archive
Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).
Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.
For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with "biologic" drugs.
In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model.
Since the passage of the Family Smoking Prevention and Tobacco Control Act in 2009, the U.S. Food and Drug Administration has met the ambitious implementation deadlines set forth in the law, the agency said Wednesday at a congressional briefing hosted by the American Association for Cancer Research.
› Verified 6 days ago
Robert J Brumback, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3333 North Calvert Street, Suite 400, Baltimore, MD 21218 Phone: 410-554-2270 Fax: 410-261-2726 | |
Dr. Milford Howarth Marchant Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2900 S Hanover St, Baltimore, MD 21225 Phone: 410-350-8336 Fax: 410-350-7178 | |
Dr. Michelle Ghert, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 110 S Paca St Fl 6, Baltimore, MD 21201 Phone: 614-397-2721 | |
Henry R Boucher, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3333 North Calvert Street, Suite 400, Baltimore, MD 21218 Phone: 410-554-2270 Fax: 410-261-2726 | |
John J Carbone, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3001 S Hanover St, Gruehn Bldg, Ste 502, Baltimore, MD 21225 Phone: 410-350-8300 | |
Dr. Dawn Laporte, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Rm 5210, Baltimore, MD 21287 Phone: 410-955-3134 | |
Paul C Mcafee, M.D., MBA Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3333 N Calvert St Ste 655, Baltimore, MD 21218 Phone: 410-554-2175 Fax: 410-554-2917 |